Advertisement

European Journal of Clinical Pharmacology

, Volume 43, Issue 6, pp 625–628 | Cite as

Heating and cooling of the nitroglycerin patch application area modify the plasma level of nitroglycerin

  • T. O. Klemsdal
  • K. Gjesdal
  • J. -E. Bredesen
Originals

Summary

19 healthy volunteers wore a nitroglycerin patch releasing 10 mg per 24 h for 2 h. Subsequently, the skin area surrounding the patch was exposed to 15 min of local heating with an infrared bulb (Group A, n =10), or local cooling with an ice-pack (Group B, n = 9). The patch was protected by an insulating shield (Styrofoam).

After 10 min of heating, the median (Walsh) plasma nitroglycerin level increased from 3.1 to 7.6 nmol·1−1. Body temperature remained constant. After 15 min of cooling the median plasma level had dropped from 2.1 to 1.4 nmol·1−1.

The results demonstrate that changes in skin temperature may cause extensive short-term changes in the bioavailability of nitroglycerin. Presumably, a subcutaneous or cutaneous reservoir builds up during transdermal treatment, and changes in regional cutaneous blood flow affect the rate of drainage from the reservoir into the systemic circulation.

Key words

Glyceryl trinitrate transdermal patch, pharmacokinetics, cutaneous circulation, skin temperature 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nimmo WS (1990) The promise of transdermal drug delivery. Br J Anesth 64: 7–10Google Scholar
  2. 2.
    Chien YW (1984) Pharmaceutical considerations of transdermal nitroglycerin delivery: The various approaches. Am Heart J 108: 207–216Google Scholar
  3. 3.
    Barkve TF, Langseth-Manrique K, Bredesen JE, Gjesdal K (1986) Increased uptake of transdermal glyceryl trinitrate during physical exercise and during high ambient temperature. Am Heart J 112:537–541Google Scholar
  4. 4.
    Weber S, de Lauture D, Rey E, Darragon T, Severins JP, Ditisheim A, Olive G, Degeorges M (1987) The effects of moderate sustained exercise on the pharmacokinetics of nitroglycerin. Br J Clin Pharmacol 23: 103–105Google Scholar
  5. 5.
    Lefebvre RA, Bogaert MG, Teirlynck O, Sioufi A, Dubois JP (1990) Influence of exercise on nitroglycerin plasma concentrations after transdermal application. Br J Clin Pharmacol 30: 292–296Google Scholar
  6. 6.
    Gjesdal K, Klemsdal TO, Rkrykke E, Bredesen E, (1991) Transdermal nitrate therapy: bioavailability during exercise increases transiently after the daily change of patch. Br J Clin Pharmacol 31: 560–562Google Scholar
  7. 7.
    Müller P, Imhof PR, Burkart F, Chu LC, Gerardin A (1982) Human pharmacological studies on a new transdermal system containing nitroglycerin. Eur J Clin Pharmacol 22: 473–480Google Scholar
  8. 8.
    Karim A (1983) Transdermal absorption of nitroglycerin from microseal drug delivery (MDD) system. Angiology 34:11–22Google Scholar
  9. 9.
    Lindberg LG, Tamura T, Öberg PA (1991) Photoplethysmography. Part 1. Comparison with laser Doppler flowmetry. Med Biol Eng Comput 29: 40–47Google Scholar
  10. 10.
    Langseth-Manrique K, Bredesen JE, Greibrokk T (1985) Rapid isothermal gas-liquid chromatographic determination of nitroglycerin in plasma with use of an electron capture detector II. J Chromatogr 349: 421–424Google Scholar
  11. 11.
    Yum SI (1989) Transdermal therapeutic systems and rate controlled drug delivery. Med Prog Technol 15: 47–52Google Scholar
  12. 12.
    Wolff HM, Bonn R (1989) Principles of transdermal nitroglycerin administration. Eur Heart J 10 [Suppl A]: 26–29Google Scholar
  13. 13.
    Shaw JE (1984) Pharmacokinetics of nitroglycerin and clonidine delivered by the transdermal route. Am Heart J 108: 217–223Google Scholar
  14. 14.
    Mcniff EF, Yacobi A, Young-Chang FM, Golden LH, Goldfarb A, Fung HL (1981) Nitroglycerin pharmacokinetics after intravenous infusion in normal subjects. J Pharm Sci 70: 1054–1058Google Scholar
  15. 15.
    Schneider W, Kaltenbach M (1986) Dosiswirkungsbeziehungen bei der Therapie der Angina pectoris mit Nitraten. Z Kardiol 75: 61–67Google Scholar
  16. 16.
    Metelitsa VI, Martsevich SY, Piotrovskii VK, Ryabokon OS, Blagodatskikh SV (1987) New transdermal and transmucosal nitro-glycerin delivery systems in patients with ischemic heart disease. Eur J Clin Pharmacol 32: 5–10Google Scholar
  17. 17.
    Imhof PR, Ott B, Frankhauser P, Chu LC, Hodler J (1980) Difference in nitroglycerin dose-response in the venous and arterial beds. Eur J Clin Pharmacol 18: 455–460Google Scholar
  18. 18.
    Parker JO, Fung HL (1984) Transdermal nitroglycerin in angina pectoris. Am J Cardiol 54: 471–476Google Scholar
  19. 19.
    Bogaert MG (1987) Clinical pharmacokinetics of glyceryl trinitrate following the use of systemic and topical preparations. Clin Pharmacokinet 12: 1–11Google Scholar
  20. 20.
    Gumbleton M, Benet LZ (1990) Pharmacological activity of the dinitrate metabolites of nitroglycerin following their oral administration to healthy volunteers. Br J Clin Pharmacol 31: 211–213Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • T. O. Klemsdal
    • 1
  • K. Gjesdal
    • 1
  • J. -E. Bredesen
    • 1
  1. 1.Department of Cardiology and Division of Clinical Pharmacology and ToxicologyOslo University Hospital UllevålOsloNorway

Personalised recommendations